Health Care & Life Sciences » Biotechnology | Enzo Biochem Inc.

Enzo Biochem Inc. | Cash Flow

Fiscal year is August-July. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
18,237.00
9,977.00
2,285.00
45,286.00
2,504.00
10,321
Depreciation, Depletion & Amortization
4,605.00
3,971.00
3,789.00
3,840.00
3,598.00
3,130
Other Funds
5,557.00
3,989.00
4,039.00
3,927.00
3,854.00
5,807
Funds from Operations
8,834.00
2,035.00
5,439.00
52,993.00
4,948.00
1,384
Changes in Working Capital
1,182.00
338.00
9,139.00
133.00
5,153.00
1,351
Net Operating Cash Flow
10,016.00
1,697.00
3,700.00
53,126.00
205.00
2,735
Capital Expenditures
988.00
838.00
1,783.00
1,530.00
1,753.00
Net Investing Cash Flow
971.00
833.00
1,752.00
1,512.00
1,749.00
Issuance/Reduction of Debt, Net
2,990.00
625.00
463.00
2,021.00
2,122.00
Net Financing Cash Flow
4,815.00
10,917.00
6,225.00
1,931.00
1,669.00
Net Change in Cash
6,069.00
8,448.00
654.00
49,668.00
3,610.00
Free Cash Flow
11,004.00
2,535.00
5,483.00
51,596.00
1,958.00
Deferred Taxes & Investment Tax Credit
759.00
18.00
104.00
60.00
-
-
Other Sources
17.00
5.00
31.00
18.00
4.00
Change in Capital Stock
1,825.00
11,542.00
6,688.00
90.00
453.00
Exchange Rate Effect
103.00
61.00
119.00
15.00
13.00

About Enzo Biochem

View Profile
Address
60 Executive Boulevard
New York New York 11735
United States
Employees -
Website http://www.enzo.com
Updated 07/08/2019
Enzo Biochem, Inc. engages in the research, development, and market of pharmaceutical products. Its medicines target the following conditions: inflammatory bowel disease, uveitis, human immunodeficiency virus, diabetes, and bone disorders. The company was founded by Elazar Rabbani, Barry W.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.